Xenon Pharmaceuticals Experienced an Exceptionally High Option Volume

On Wednesday, the options market witnessed unusual activity concerning Xenon Pharmaceuticals I.N.C.
‍

Investors acquired put options on a total of 4,063 shares of the company's stock. Compared to the average daily volume of 165 put options, this indicates a 2,362 percent increase in the amount of put options traded.
‍

Several institutional investors have recently purchased and sold the company's stock shares. These deals occurred very recently.
‍

The company increased by 36.1%, the fraction of Xenon Pharmaceuticals shares owned by UBS Group AG as of the end of the fourth quarter.
‍

After three months, UBS Group AG acquired an additional 1,236 shares of the biopharmaceutical business and expanded its shareholding.
‍

This takes the total number of shares held by the firm to 4,662, now worth $184,000.00.
‍

In the final three months of 2018, the Swiss National Bank boosted its ownership of Xenon Pharmaceuticals stock by 4.0 percentage points.
‍

The Swiss National Bank currently holds a total of 112,700 shares in the biopharmaceutical business after acquiring an additional 4,300 shares in the prior quarter, bringing its total to 112,700.
‍

Currently, these shares are selling for $4,444,000 per unit.
‍

The Arizona State Retirement System acquired an additional 6.0% of Xenon Pharmaceuticals shares during the most recent quarter, bringing its total holdings to 100%. Now Arizona State Retirement System n owns 13,177 shares of the firm, which has a market value of $520,000.
‍

This is due to the recent acquisition of an extra 750 shares, which increased the total number of shares owned by the system to 13,177.
‍

During the final three months of 2018, the proportion of Xenon Pharmaceuticals shares owned increased by 33.3%.
‍

Fox Run Management L.L.C. now directly owns 12,975 shares of the biopharmaceutical business following the recent acquisition of an additional 3,244 shares during the most recent quarter.

‍

According to the stock's current closing price, this gives the firm a worth of $512,000. In the final three months of 2018, Handelsbanken Fonder AB raised the amount it had invested in Xenon Pharmaceuticals by 33.0%. In the most recent quarter, Handelsbanken Fonder AB acquired an additional 3,500 shares, bringing its total holdings in the biopharmaceutical firm to 14,100. These shares, whose current market worth is $556,000, were acquired.

‍

Institutional investors and hedge funds control 92.49% of the company's total shares, constituting the majority of shareholders.

‍

In other news, on November 23, it was announced that Director Gary Patou sold 2,057 shares of the company's stock.

‍

The number of shares sold amounted to $70,616.81, with an average price per share of $34.33.

‍

As a direct result of the transaction, the director is now the direct owner of 23,573 shares of the firm, and the current market value of these shares is $809,261.09.

‍

Insiders own 6.06 % of the total number of outstanding shares.
‍

Several experts specializing in equities research have lately shared their opinions on the stock with the public.
‍

Monday, December 12, marked the beginning of Cowen's Xenon Pharmaceuticals shares coverage. They suggested that the stock "outperforms" investors' expectations. According to a report issued on October 18, Raymond James is now responsible for providing coverage for Xenon Pharmaceuticals.
‍

They have given the firm a "outperform" rating, and their price target for the stock is $52.00.
‍

In a report released on January 31, the Royal Bank of Canada lifted its "outperform" rating on Xenon Pharmaceuticals to $51.00 and raised its price target for the firm from $49.00 to $51.00.
‍

The stock price of the company reflected both of these adjustments. Wells Fargo & Company disclosed its coverage of Xenon Pharmaceuticals in a report made accessible to the general public on November 28.
‍

They assigned the company an "overweight" rating and forecasted a price of $50.00 per share for the stock mentioned above. In a research report released on Friday, November 11, Guggenheim decreased their price target on Xenon Pharmaceuticals from $53.00 to $49.00 and accorded the stock a "buy" rating.
‍

Twelve experts have recommended that investors acquire the stock, while only one analyst has recommended that investors sell their shares.
‍

According to data provided by Trade Algo, website users have rated the firm as a "Moderate Buy" and have set an average price target of $50.78 for the stock.
‍

Thursday's opening price on the NASDAQ XENE market was $38.85 per share.

During one year of trade, the price of a share of Xenon Pharmaceuticals has fluctuated between $24.94 and $41.39.
‍

For the previous 200 trading days, the stock has had a moving average price of $36.85, while the moving average price for the last 50 trading days is $37.82.
‍

The firm is predicted to have a market value of $2.43 billion, a price-to-earnings ratio of -19.04, and a beta of 1.
‍

The biopharmaceutical business announced a quarterly loss of $0.57 per share, $0.05 less than the average estimate of $0.52 per share. The return on equity for Xenon Pharmaceuticals was negative by 17.31%, while the net margin was negative by 862.06%.

‍

The company only generated $0.13 million in sales for the quarter, much less than the $6.40 million industry experts predicted. For the current fiscal year, analysts forecast that Xenon Pharmaceuticals will generate earnings per share (EPS) of -2.1.

‍